在本综述中，我们分析了新生物标志物开发研究的当前状态，这些标志物可能在转移性肾细胞癌（mRCC）治疗中有用。结合肿瘤基础的生物标志物（基因表达谱）和血液基础的生物标志物（ctDNA，细胞因子）有助于获取有关RCC的信息，可能在决策过程中具有重要意义。肾细胞癌（RCC）是男性中第六种最常诊断的肿瘤，女性中为第十种，负责分别占所有诊断癌症的5％和3％。转移阶段代表了诊断时不可忽视的一部分，其具有不良预后的特点。尽管临床特征和预后评分可以指导临床医生治疗该疾病的方法，但是预测治疗反应的生物标志物仍是一个尚未满足需求的领域。© 2023年。作者（独家许可Springer Science+Business Media，LLC，Springer Nature的一部分）。

In this review, we analyze the current state of research in development of new biomarkers that may be useful in managing metastatic renal cell carcinoma (mRCC) setting.Combining tumor-based biomarkers (gene expression profile) and blood-based biomarkers (ctDNA, cytokines) would be helpful in acquiring information regarding RCC and might be significant in the decision-making process. Renal cell carcinoma (RCC) is the sixth most frequently diagnosed neoplasm in men and tithe in women, making it responsible for 5% and 3% of all diagnosed cancers respectively. Metastatic stage represents a non-negligible percentage at diagnosis and is characterized by poor prognosis. Despite clinical features and prognostic score could guide clinicians in therapeutic approach of this disease, biomarkers predictive of response to treatment remain an unmet need.© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.